HALOPROGIN — Competitive Intelligence Brief

HALOPROGIN (HALOPROGIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: haloprogin. Area: Pain.

marketed haloprogin Adenosine receptor A3 Pain Small molecule

Target snapshot

HALOPROGIN (HALOPROGIN) — Westwood Squibb.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HALOPROGIN TARGET	HALOPROGIN	Westwood Squibb	marketed	haloprogin	Adenosine receptor A3	1982-01-01
Singulair	montelukast	Merck & Co.	marketed	Leukotriene receptor antagonist (LTRA)	Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2	1998-02-20
Adenocard	ADENOSINE	Astellas Pharma	marketed	Adenosine Receptor Agonist [EPC]	Adenosine receptor A3	1989-01-01
Tenoretic 100	ATENOLOL	Twi Pharms	marketed	beta-Adrenergic Blocker [EPC]	Adenosine receptor A3	1981-01-01
Oxtriphylline	choline theophyllinate	Warner Chilcott Llc	marketed	choline theophyllinate	Adenosine receptor A3, Alkaline phosphatase, tissue-nonspecific isozyme, Adenosine receptor A1	1981-01-01
Dulcotil	SULOCTIDIL		marketed	suloctidil	Adenosine receptor A3, Substance-K receptor, 5-hydroxytryptamine receptor 1A	1979-01-01
Estrobene	DIETHYLSTILBESTROL	Tablicaps	marketed	Standardized Chemical Allergen [EPC]	Sodium/nucleoside cotransporter 1, 5-hydroxytryptamine receptor 6, Adenosine receptor A3	1973-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (haloprogin class)

1. Westwood Squibb · 1 drug in this class